Print Reset

AETNA BETTER HEALTH® OF VIRGINIA REQUEST FORM

Tysabri ® (natalizumab)

Fax back to: 1-855-799-2553

If the following information is not complete, correct, or legible, the PA process can be delayed.

Please use one form per member.

MEMBER INFORMATION

Last Name:

First Name:

Medicaid ID Number:

Date of Birth: __ __ – __ __ – __ __ __ __

Weight in Kilograms: _____

PRESCRIBER INFORMATION

Last Name:

First Name:

NPI Number:

Phone Number: __ __ __ – __ __ __ – __ __ __ __

Fax Number: __ __ __ – __ __ __ – __ __ __ __

DRUG INFORMATION

Drug Name/Form: _____

Strength: _____

Dosing Frequency: _____

Length of Therapy: _____

Quantity per Day: _____

(Form continued on next page.)

Member's Last Name:

Member's First Name:

DIAGNOSIS AND MEDICAL INFORMATION

For an initial request for Multiple Sclerosis, complete the following to receive a 6-month approval:

1. Is the member at least 18 years of age? **AND**

   ☐ Yes ☐ No

2. Has the member prescriber and member enrolled in and meet the conditions of the TOUCH (applicable to Tysabri) or REMS (applicable to Tyruko) programs? **AND**

   ☐ Yes ☐ No

3. Does the member have a documented negative JCV antibody ELISA test within the past 6 months? **AND**

   ☐ Yes ☐ No

4. Will the requested product not be used in combination with antineoplastic, immunosuppressant, or immunomodulating agents? **AND**

   ☐ Yes ☐ No

5. Is the member immunocompetent? **AND**

   ☐ Yes ☐ No

6. Will Tysabri be used as a single therapy? **AND**

   ☐ Yes ☐ No

7. Does the member have a confirmed diagnosis of multiple sclerosis (MS) as documented by laboratory report (i.e., MRI); **AND**

   ☐ Yes ☐ No

8. Does the member have a diagnosis of a relapsing form of MS (i.e., relapsing-remitting MS (RRMS)*, active secondary progressive disease (SPMS)**, or clinically isolated syndrome (CIS)***]? **OR**

   ☐ Yes ☐ No

(Form continued on next page.)

Member's Last Name:

Member's First Name:

For a renewal request for Multiple Sclerosis, complete the following to receive a 12-month approval:

1. Does the member continue to meet the relevant criteria identified in the initial criteria? **AND**

   ☐ Yes ☐ No

2. Does the member have an absence of unacceptable toxicity from the drug? **AND**

   ☐ Yes ☐ No

3. Is the member being continuously monitored for response to therapy indicates a beneficial response?

   ☐ Yes ☐ No

For an initial request for Crohn's Disease, complete the following questions to receive a 6-month approval:

1. Is the member at least 18 years of age? **AND**

   ☐ Yes ☐ No

2. Has the member prescriber and member enrolled in and meet the conditions of the TOUCH (applicable to Tysabri) or REMS (applicable to Tyruko) programs? **AND**

   ☐ Yes ☐ No

3. Does the member have a documented negative JCV antibody ELISA test within the past 6 months? **AND**

   ☐ Yes ☐ No

4. Will the requested product not be used in combination with antineoplastic, immunosuppressant, or immunomodulating agents? **AND**

   ☐ Yes ☐ No

5. Is the member immunocompetent? **AND**

   ☐ Yes ☐ No

6. Does the member have moderate to severe active disease? **AND**

   ☐ Yes ☐ No

7. Has the physician has assessed baseline disease severity utilizing an objective measure/tool; **AND**

   ☐ Yes ☐ No

8. Does the member have a documented trial and failure on ONE oral immunosuppressive therapy for at least 3 months, unless use is contraindicated, such as corticosteroids, methotrexate, azathioprine, and/or 6-mercaptopurine? **AND**

   ☐ Yes ☐ No

(Form continued on next page.)

Member's Last Name:

Member's First Name:

9. Does the member have a two of the preferred Cytokine and CAM antagonist agents for Crohn's Disease (see Cytokine and CAM Antagonists on the PDL)? **AND**

   ☐ Yes ☐ No

10. Will Tysabri be used as single agent therapy [Not used concurrently with another biologic drug or immunosuppressant (e.g., 6-mercaptopurine, azathioprine, cyclosporine, methotrexate, etc.) used for Crohn's Disease?

    ☐ Yes ☐ No

For a renewal request for Crohn's Disease, complete the following questions:

1. Initial renewal only (6-month approval):

   a. Has the member been tapered off of oral corticosteroids within 6 months of starting Tysabri? **AND**;

      ☐ Yes ☐ No

   b. Has the disease responded as indicated by improvement in signs and symptoms compared to baseline such as endoscopic activity, number of liquid stools, presence and severity of abdominal pain, presence of abdominal mass, body weight compared to IBW, hematocrit, presence of extra intestinal complications, tapering or discontinuation of corticosteroid therapy, use of anti-diarrheal drugs, and/or an improvement on a disease activity scoring tool?

      ☐ Yes ☐ No

2. Subsequent renewals (12-month approval):

   a. Does the member not require additional steroid use that exceeds 3 months in a calendar year to control their Crohn's disease? **AND**

      ☐ Yes ☐ No

   b. Has the disease responded as indicated by improvement in signs and symptoms compared to baseline such as endoscopic activity, number of liquid stools, presence and severity of abdominal pain, presence of abdominal mass, body weight compared to IBW, hematocrit, presence of extra intestinal complications, tapering or discontinuation of corticosteroid therapy, use of anti-diarrheal drugs, and/or an improvement on a disease activity scoring tool?

      ☐ Yes ☐ No

(Form continued on next page.)

Member's Last Name:

Member's First Name:

***Definitive diagnosis of MS with a relapsing-remitting course is based upon BOTH dissemination in time and space. Unless contraindicated, MRI should be obtained (even if criteria are met).**	
Dissemination in time (Development/appearance of new CNS lesions over time)	**Dissemination in space** (Development of lesions in distinct anatomical)
▪ ≥ 2 clinical attacks; **OR** ▪ 1 clinical attack AND one of the following: – MRI indicating simultaneous presence of gadolinium-enhancing and non-enhancing lesions at any time or by a new T2- hyperintense or gadolinium-enhancing lesion on follow-up MRI compared to baseline scan – CSF-specific oligoclonal bands	▪ ≥ 2 lesions; ▪ 1 lesion AND one of the following: – Clear-cut historical evidence of a previous attack involving a lesion in a distinct anatomical location – MRI indicating ≥ 1 T2-hyperintense lesions characteristic of MS in ≥ 2 of 4 areas of the CNS (periventricular, r juxtacortical, infratentorial, or spinal cord)
****Active secondary progressive MS (SPMS) is defined as the following:**	
▪ Expanded Disability Status Scale (EDSS) score ≥ 3.0; **AND** ▪ Disease is progressive ≥ 3 months following an initial relapsing-remitting course (i.e., EDSS score increase by 1.0 in members with EDSS ≤5.5 or increase by 0.5 in members with EDSS ≥6); **AND** – ≥ 1 relapse within the previous 2 years; **OR** – Member has gadolinium-enhancing activity OR new or unequivocally enlarging T2 contrast-enhancing lesions as evidenced by MRI	
*****Definitive diagnosis of CIS is based upon <u>ALL</u> of the following:**	
▪ A monophasic clinical episode with member-reported symptoms and objective findings reflecting a focal or multifocal inflammatory demyelinating event in the CNS ▪ Neurologic symptom duration of at least 24 hours, with or without recovery ▪ Absence of fever or infection ▪ Member is not known to have multiple sclerosis	
******Definitive diagnosis of MS with a primary progressive course is based upon the following:**	
▪ 1 year of disability progression independent of clinical relapse; **AND** ▪ TWO of the following: – ≥ 1 T2-hyperintense lesion characteristic of MS in one or more of the following regions of the CNS: periventricular, cortical or juxtacortical, or infratentorial – ≥ 2 T2-hyperintense lesions in the spinal cord – Presence of CSF-specific oligoclonal bands	

(Form continued on next page.)

Member's Last Name:

Member's First Name:

Prescriber Signature (Required) **Date**

By signature, the physician confirms the above information is accurate and verifiable by member records.

Please include ALL requested information; Incomplete forms will delay the PA process.
Submission of documentation does NOT guarantee coverage.